Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics is a clinical-stage biotechnology company that is focused on developing novel bifunctional biologics for solid tumors, with a main focus on ficerafusp alfa, a bifunctional antibody that combines two clinically validated targets. The company is expected to have key catalysts in 2026, including data presentations and potential revenue projections from ficerafusp alfa for patients with HPV-negative HNSCC and CRC. The company's financial outlook also seems positive, with a substantial cash balance and successful fundraising in a recent public offering. Overall, Bicara Therapeutics shows potential for future growth and success in the biopharmaceutical industry.

Bears say

Bicara Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to the company's reliance on one product, ficerafusp alfa, which has yet to receive approval. While the company's recent financial results and program updates are promising, its cash position may not be sufficient to support its operations through to a potential launch, and success of ficerafusp alfa is not guaranteed. Additionally, the company is only targeting a small portion of the eligible market with this product, putting its long-term commercial viability at risk.

BCAX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 11 analysts, BCAX has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.